Optic Pathway (Optic–Hypothalamic) Gliomas

Status: draft · Last updated 2026-11-18 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • OPGs are low-grade, with high survival (about 98% at 5 years in one series). Treat to protect vision and the hypothalamus .
  • NF1: both optic nerves, more indolent. Sporadic: chiasm and hypothalamus, more progressions .
  • First line: carboplatin and vincristine.
    • 5-year EFS about 39% in non-NF1 vs 69% in NF1, in low-grade glioma overall (not OPG-specific) .
    • Starting under age 1 predicts progression .
  • Visual acuity is the key endpoint, and it correlates poorly with imaging. About a third of children with NF1 OPG improve after chemotherapy .
  • Selumetinib in recurrent sporadic OPG: 2-year PFS 78% .
  • Surgery is selective: biopsy, CSF diversion, or debulking for mass effect.
    • Debulking was associated with worse visual and endocrine outcomes than biopsy in one small series ; any surgery was associated with endocrine–metabolic dysfunction in infants .
  • Infants: diencephalic syndrome, hypothalamic involvement, surgery and radiotherapy all raise endocrine and metabolic risk .

Landmark papers

  • COG A9952 (Ater et al., J Clin Oncol 2012): a randomized trial of carboplatin–vincristine vs TPCV (274 children under 10 with low-grade glioma). 5-year EFS was 39% vs 52% (P = .10 by stratified log-rank; a cure-model analysis favored TPCV) .
  • Fisher et al., Neuro Oncol 2012: multicenter NF1 OPG visual outcomes after chemotherapy. Visual acuity improved in 32%, was stable in 40% and declined in 28%, and correlated poorly with imaging, which made vision the key endpoint .
  • PBTC-029 selumetinib (Fangusaro et al., Neuro Oncol 2021): recurrent sporadic optic–hypothalamic glioma (25 patients). 2-year PFS was 78%, and vision improved in 21% of 19 evaluable patients .

Optic pathway gliomas (OPGs) are low-grade gliomas, mostly pilocytic astrocytomas. They arise along the optic nerves, chiasm, tracts and radiations, often extending into the hypothalamus (optic–hypothalamic glioma) .

Jason S. Hauptman, MD, PhD© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure from Hauptman's High Yield Thoughts in Pediatric Neurosurgery (pedsneurosurg.org). Do not copy, reproduce, redistribute or adapt without written permission.https://www.pedsneurosurg.org/hy-peds-ns:optic_pathway_glioma:6c63f86a2dd061f9© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure; please do not copy, reproduce or redistribute without written permission.Basal view of the visual pathway with modified Dodge zones (optic nerve, chiasm, hypothalamus, posterior pathway); a midsagittal chiasmatic-hypothalamic glioma filling the suprasellar cistern, elevating the third-ventricle floor and blocking the foramina of Monro, with the pituitary below and the anterior cerebral arteries draped over it; and NF1 bilateral optic-nerve versus sporadic chiasmatic-hypothalamic patterns(A) VISUAL PATHWAY, BASAL VIEW: MODIFIED DODGE ZONESglobeoptic nervechiasmhypothalamusposterior pathway(tracts, lateral geniculate,radiations)(B) CHIASMATIC-HYPOTHALAMIC GLIOMA (MIDSAGITTAL)enlarged lateral ventricle(foramina of Monro blocked)third-ventricle floor elevatedanterior cerebral arteriesdraped over the tumorglioma fills thesuprasellar cisternpituitary below(C) NF1 VERSUS SPORADIC PATTERNNF1:both optic nerves,often indolentsporadic:chiasm / hypothalamus,more progressions
Optic pathway glioma. (a) Basal view of the visual pathway (globes, optic nerves, chiasm, tracts) with the modified Dodge zones: optic nerve, chiasm (central/lateral), hypothalamus, posterior pathway. (b) Midsagittal view: a chiasmatic–hypothalamic glioma filling the suprasellar cistern, elevating the third-ventricle floor and obstructing the foramina of Monro, with the pituitary below. (c) NF1 versus sporadic patterns: bilateral fusiform optic nerves (NF1) versus a bulky chiasmatic/hypothalamic mass (sporadic). Not to scale.

Classification and patterns

Presentation

Medical treatment

Role of surgery

Related topics

References

  1. Taylor T, Jaspan T, Milano G, et al. Radiological classification of optic pathway gliomas: experience of a modified functional classification system. Br J Radiol 2008;81(970):761–766. doi:10.1259/bjr/65246351. PMID 18796556. verified
  2. Del Baldo G, Cacchione A, Dell'Anna VA, et al. Rethinking the management of optic pathway gliomas: a single center experience. Front Surg 2022;9:890875. doi:10.3389/fsurg.2022.890875. PMID 35784925. verified
  3. Bennebroek CAM, van Zwol J, Montauban van Swijndregt MC, et al. A retrospective, nationwide, multicenter study on diagnosis and treatment outcome of pediatric optic pathway/hypothalamic gliomas including analysis of risk factors for progression after systemic anticancer therapy. Cancers (Basel) 2025;17(5):716. doi:10.3390/cancers17050716. PMID 40075564. verified
  4. Picariello S, Cerbone M, D'Arco F, et al. A 40-year cohort study of evolving hypothalamic dysfunction in infants and young children (<3 years) with optic pathway gliomas. Cancers (Basel) 2022;14(3):747. doi:10.3390/cancers14030747. PMID 35159015. verified
  5. Ater JL, Zhou T, Holmes E, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J Clin Oncol 2012;30(21):2641–2647. doi:10.1200/JCO.2011.36.6054. PMID 22665535. verified
  6. Ater JL, Xia C, Mazewski CM, et al. Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: a report from the Children's Oncology Group. Cancer 2016;122(12):1928–1936. doi:10.1002/cncr.29987. PMID 27061921. verified
  7. Fisher MJ, Loguidice M, Gutmann DH, et al. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol 2012;14(6):790–797. doi:10.1093/neuonc/nos076. PMID 22474213. verified
  8. Fangusaro J, Onar-Thomas A, Poussaint TY, et al. A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. Neuro Oncol 2021;23(10):1777–1788. doi:10.1093/neuonc/noab047. PMID 33631016. verified

Verification (2026-11-18):

Caveats: